S&P 500 cuts losses as Nvidia climbs ahead of results
ELK CITY, Idaho - Therapeutic Solutions International, Inc. (OTC:TSOI), a company specializing in immune modulation for disease treatment, with a current market capitalization of $1.77 million and negative EBITDA of $3.28 million, has announced its plan to voluntarily delist from public trading. The decision, approved by the Board of Directors and a majority of voting shareholders on April 22, 2025, will see the company withdraw its securities from listing and registration on the Exchange and OTC Markets.
In a move described by CEO Timothy G Dixon as a "necessary pause," the company aims to protect itself from what it perceives as a hostile market environment, characterized by predatory trading and short attacks. The company, once valued at $400 million, has seen its market cap plummet to below $10 million over the past three years. According to InvestingPro data, the company is quickly burning through cash and operates with a significant debt burden, with a concerning current ratio of 0.27. Get access to 9 more exclusive ProTips and detailed financial metrics with InvestingPro.
As part of the delisting process, Therapeutic Solutions International filed a Form 8-K with the SEC, initiating a 10-day waiting period. This will be followed by the filing of Form 25 to notify the removal from listing and registration, and subsequently, Form 15 to certify the termination of registration.
Dixon emphasized that the delisting is not indicative of the company’s failure but is a strategic step to refocus on its core subsidiaries: Breathe Biologics, Campbell Neurosciences, and Res Nova Bio. Despite showing a strong return of 50% over the last week, InvestingPro analysis indicates the company’s overall financial health score remains "FAIR" at 1.89 out of 5. These subsidiaries are expected to drive future technology and shareholder value, potentially through sales or partnerships that could inject liquidity back into the parent company.
In a statement to shareholders, Dixon promised that any future proceeds from these initiatives would be shared with shareholders, possibly through dividends or a stock buy-back program. This commitment is positioned as a gesture of appreciation for shareholder loyalty and patience during this transitional period.
Therapeutic Solutions International’s decision to go dark comes as the company seeks to rebuild and recover away from the pressures of the public market. Despite the delisting, the company assures stakeholders that it is not going away, but rather turning inward to strengthen its core operations.
The information in this article is based on a press release statement from Therapeutic Solutions International, Inc.
In other recent news, Therapeutic Solutions International has announced a one-time loyalty dividend for its shareholders, involving shares of its subsidiary, Breathe Biologics. Shareholders as of the market close on March 3, 2025, will be eligible to receive this dividend, with the conversion rate set at approximately 0.1293% of a Breathe Biologics share per Therapeutic Solutions share owned. The company, which owns 86.53% of Breathe Biologics, will allocate 7,500,000 shares for this dividend. This offer will remain open for 60 days, ending on May 3, 2025. Shareholders must submit a form and a brokerage statement verifying their ownership to receive their dividend. Upon verification, they will receive a Book Entry Statement for their new holdings in Breathe Biologics. This move is intended to reward shareholders and demonstrate confidence in the subsidiary’s potential. The details are outlined in the company’s SEC filings and a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.